je.st
news
Tag: lung
USA Truck CEO John Simone Treated for Lung Cancer
2015-05-08 01:30:45| Trucking - Topix.net
USA Truck Inc. CEO John Simone said Thursday that he is being treated for lung cancer, and that while he and his doctors are optimistic, he's not sure yet when he'll return to the Van Buren trucking company.
Tiny Corbus looks to take on Vertex with experimental lung drug
2015-05-05 01:23:06| Biotech - Topix.net
Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. REUTERS: Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco.
Tags: with
drug
experimental
tiny
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
2015-04-29 05:17:09| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S
Tags: cell
treatment
cancer
patients
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in nave and previously-treated patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
advanced
journal
published
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2015-04-19 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
application
license
cell
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »